FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996503485> ?p ?o ?g. }

• W2996503485 endingPage "410" @default.
• W2996503485 startingPage "399" @default.
• W2996503485 abstract "A more affordable pneumococcal conjugate vaccine (PCV) that provides comparable protection to current PCVs is needed to ensure sustainable access in resource-limited settings. Serum Institute of India Pvt. Ltd.'s PCV candidate (SIIPL-PCV) has the potential to meet this need as manufacturing efficiency has been optimized and the vaccine targets the most prevalent disease-causing serotypes in Africa and Asia. We report SIIPL-PCV's safety, tolerability, and immunogenicity in adults, toddlers, and infants in The Gambia.This phase 1/2, randomized, double-blind trial sequentially enrolled 34 PCV-naive adults (18-40 years old), 112 PCV (Prevenar 13® [PCV13])-primed toddlers (12-15 months old), and 200 PCV-naive infants (6-8 weeks old), who were randomized (1:1) to receive SIIPL-PCV or a licensed comparator vaccine. Infants received three-doses of SIIPL-PCV or PCV13 at 6, 10, and 14 weeks of age co-administered with routine Expanded Program on Immunization (EPI) vaccines. Reactogenicity was solicited through seven-days post-vaccination; unsolicited adverse events (AEs) were assessed throughout the study. The safety and immunogenicity of a matching booster at 10-14 months of age were evaluated in a subset of 96 infants. Immune responses were evaluated post-primary and pre- and post-booster vaccinations.Reactogenicity was primarily mild-to-moderate in severity. In infants, the most common solicited reactions were injection-site tenderness and fever, with no meaningful treatment-group differences. There were no serious or severe vaccine-related AEs and no meaningful trends in SAEs, vaccine-related AEs, or overall AEs. Infant post-primary seroresponse rates (IgG level ≥ 0.35 µg/mL) were ≥89% for all serotypes except 6A (79%) in the SIIPL-PCV group. IgG GMCs were >1 µg/mL for all serotypes in both SIIPL-PCV and PCV13 groups. Post-booster GMCs were comparable between groups.SIIPL-PCV was well-tolerated, had an acceptable safety profile, and was immunogenic for all vaccine serotypes. Results support the evaluation of SIIPL-PCV in a phase 3 non-inferiority trial. Clinicaltrials.gov: NCT02308540." @default.
• W2996503485 created "2019-12-26" @default.
• W2996503485 creator A5000826082 @default.
• W2996503485 creator A5003983735 @default.
• W2996503485 creator A5012110091 @default.
• W2996503485 creator A5012441871 @default.
• W2996503485 creator A5015087698 @default.
• W2996503485 creator A5016180624 @default.
• W2996503485 creator A5019094179 @default.
• W2996503485 creator A5026230879 @default.
• W2996503485 creator A5033153495 @default.
• W2996503485 creator A5037003642 @default.
• W2996503485 creator A5049151302 @default.
• W2996503485 creator A5060338193 @default.
• W2996503485 creator A5069576329 @default.
• W2996503485 creator A5084618796 @default.
• W2996503485 creator A5085942817 @default.
• W2996503485 date "2020-01-01" @default.
• W2996503485 modified "2023-10-14" @default.
• W2996503485 title "Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia—Results of a phase 1/2 randomized, double-blinded, controlled trial" @default.
• W2996503485 cites W1827503339 @default.
• W2996503485 cites W2010463009 @default.
• W2996503485 cites W2013400892 @default.
• W2996503485 cites W2030178991 @default.
• W2996503485 cites W2056360579 @default.
• W2996503485 cites W2072498492 @default.
• W2996503485 cites W2074074587 @default.
• W2996503485 cites W2092915795 @default.
• W2996503485 cites W2096913021 @default.
• W2996503485 cites W2103637444 @default.
• W2996503485 cites W2105654921 @default.
• W2996503485 cites W2106134483 @default.
• W2996503485 cites W2110584975 @default.
• W2996503485 cites W2122598469 @default.
• W2996503485 cites W2124067321 @default.
• W2996503485 cites W2131085519 @default.
• W2996503485 cites W2135454610 @default.
• W2996503485 cites W2148176740 @default.
• W2996503485 cites W2149176649 @default.
• W2996503485 cites W2154988929 @default.
• W2996503485 cites W2158569411 @default.
• W2996503485 cites W2166448515 @default.
• W2996503485 cites W2195509691 @default.
• W2996503485 cites W2281157579 @default.
• W2996503485 cites W2283730606 @default.
• W2996503485 cites W2337567633 @default.
• W2996503485 cites W2476595719 @default.
• W2996503485 cites W2549697535 @default.
• W2996503485 cites W2604470353 @default.
• W2996503485 cites W2611740721 @default.
• W2996503485 cites W2745134154 @default.
• W2996503485 cites W2808668519 @default.
• W2996503485 cites W2900585653 @default.
• W2996503485 cites W2904560398 @default.
• W2996503485 cites W2912971785 @default.
• W2996503485 doi "https://doi.org/10.1016/j.vaccine.2019.08.072" @default.
• W2996503485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31843266" @default.
• W2996503485 hasPublicationYear "2020" @default.
• W2996503485 type Work @default.
• W2996503485 sameAs 2996503485 @default.
• W2996503485 citedByCount "19" @default.
• W2996503485 countsByYear W29965034852020 @default.
• W2996503485 countsByYear W29965034852021 @default.
• W2996503485 countsByYear W29965034852022 @default.
• W2996503485 countsByYear W29965034852023 @default.
• W2996503485 crossrefType "journal-article" @default.
• W2996503485 hasAuthorship W2996503485A5000826082 @default.
• W2996503485 hasAuthorship W2996503485A5003983735 @default.
• W2996503485 hasAuthorship W2996503485A5012110091 @default.
• W2996503485 hasAuthorship W2996503485A5012441871 @default.
• W2996503485 hasAuthorship W2996503485A5015087698 @default.
• W2996503485 hasAuthorship W2996503485A5016180624 @default.
• W2996503485 hasAuthorship W2996503485A5019094179 @default.
• W2996503485 hasAuthorship W2996503485A5026230879 @default.
• W2996503485 hasAuthorship W2996503485A5033153495 @default.
• W2996503485 hasAuthorship W2996503485A5037003642 @default.
• W2996503485 hasAuthorship W2996503485A5049151302 @default.
• W2996503485 hasAuthorship W2996503485A5060338193 @default.
• W2996503485 hasAuthorship W2996503485A5069576329 @default.
• W2996503485 hasAuthorship W2996503485A5084618796 @default.
• W2996503485 hasAuthorship W2996503485A5085942817 @default.
• W2996503485 hasBestOaLocation W29965034851 @default.
• W2996503485 hasConcept C12590561 @default.
• W2996503485 hasConcept C126322002 @default.
• W2996503485 hasConcept C168563851 @default.
• W2996503485 hasConcept C187212893 @default.
• W2996503485 hasConcept C197934379 @default.
• W2996503485 hasConcept C203014093 @default.
• W2996503485 hasConcept C22070199 @default.
• W2996503485 hasConcept C2777704310 @default.
• W2996503485 hasConcept C2778375690 @default.
• W2996503485 hasConcept C2778866548 @default.
• W2996503485 hasConcept C2780801004 @default.
• W2996503485 hasConcept C2780868878 @default.
• W2996503485 hasConcept C2781253189 @default.
• W2996503485 hasConcept C501593827 @default.
• W2996503485 hasConcept C71924100 @default.
• W2996503485 hasConcept C86803240 @default.

• next